PROMETA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prometa, and when can generic versions of Prometa launch?
Prometa is a drug marketed by Muro and is included in two NDAs.
The generic ingredient in PROMETA is metaproterenol sulfate. Additional details are available on the metaproterenol sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prometa
A generic version of PROMETA was approved as metaproterenol sulfate by CHARTWELL on July 22nd, 1992.
US Patents and Regulatory Information for PROMETA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Muro | PROMETA | metaproterenol sulfate | SOLUTION;INHALATION | 073340-001 | Mar 30, 1992 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Muro | PROMETA | metaproterenol sulfate | SYRUP;ORAL | 072023-001 | Sep 15, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
